Correction: Updated E-mail Address – Attention Providers of Section 19 and 96 Services: Supervisory Visit Requirements for Personal Care Agencies

The previous version of this message included an incorrect email address, so we are resending this bulletin.

Personal care agencies currently conducting personal support specialist (PSS) supervision visits remotely must resume in-person visits beginning January 23, 2023. The Department will send out additional e-message reminders closer to the effective date for the change. 

Reminder: Atrezzo Upgrade

On Monday, November 7, 2022, Kepro will upgrade their web-based platform to Atrezzo Next Generation. The Atrezzo Next Generation (ANG) platform is an improved interface with enhanced security features such as Multi-Factor Authentication (MFA).   â€¯ 

Training Plan and Resources &²Ô²ú²õ±è; â¶Ä¯&²Ô²ú²õ±è;

Attention Substance Use Providers: Help fb88Care Design a New Substance Use Health Home Model

As a valued partner in the Continuum of Care for Substance Use Treatment, we would like to offer you the opportunity to assist in the expansion of Opioid Health Homes to be more inclusive of other substance use disorder (SUD) diagnoses. The Office of fb88Care Service is asking for your input on key components of services that must be included in this model and welcomes provider engagement with the process of developing this new policy.

Current PERM Audit

The State of fb88 is currently in the process of a federally mandated Payment Error Rate Measurement (PERM) audit for Reporting Year (RY) 2024. This audit covers randomly selected paid claims with a payment date from July 1, 2022, through June 30, 2023. PERM measures improper payments in Medicaid and the State Children’s Health Insurance Program (CHIP) and produces state and national level error rates for each program.  

Required Medical Records 

Attention Providers of Section 19 and 96 Services: Supervisory Visit Requirements for Personal Care Agencies

Personal care agencies currently conducting personal support specialist (PSS) supervision visits remotely must resume in-person visits beginning January 23, 2023. The Department will send out additional e-message reminders closer to the effective date for the change.  

For questions, please contact Tammy Usher.  

Reminder: Primary Care Plus (PCPlus) Application is Open

fb88Care Services is pleased to announce that we are now accepting applications for participation in fb88Care’s PCPlus program. PCPlus is a fb88Care primary care model that gives Primary Care Providers (PCPs) greater flexibility and incentives to meet fb88Care members’ healthcare needs by transitioning away from a volume-based (fee-for-service) payment system toward population-based payments tied to cost and quality-related outcomes.

Reminder: Primary Care Plus (PCPlus) Application is Open

fb88Care Services is pleased to announce that we are now accepting applications for participation in fb88Care’s PCPlus program. PCPlus is a fb88Care primary care model that gives Primary Care Providers (PCPs) greater flexibility and incentives to meet fb88Care members’ healthcare needs by transitioning away from a volume-based (fee-for-service) payment system toward population-based payments tied to cost and quality-related outcomes.

Reminder: Primary Care Plus (PCPlus) Application is Open

fb88Care Services is pleased to announce that we are now accepting applications for participation in fb88Care’s PCPlus program. PCPlus is a fb88Care primary care model that gives Primary Care Providers (PCPs) greater flexibility and incentives to meet fb88Care members’ healthcare needs by transitioning away from a volume-based (fee-for-service) payment system toward population-based payments tied to cost and quality-related outcomes.

Pfizer and Moderna Bivalent COVID-19 Vaccines Authorized to Use as Booster Doses in Children Ages 5 Years and Older

On October 17, 2022, the Office of fb88Care Services (OMS) sent an announcement that we will cover the Pfizer and Moderna bivalent COVID-19 vaccine booster doses as outlined in Emergency Use Authorizations (EUA) from the Food and Drug Administration (FDA).    &²Ô²ú²õ±è; â¶Ä¯&²Ô²ú²õ±è;